Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Publisher Name :
Date: 31-Oct-2013
No. of pages: 112

GBI Research has released the pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, GBI Research believes that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019.

Scope

  • An introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which mAbs are clinically relevant to this type of cancer.
  • In-depth analysis of the five mAbs approved for breast cancer, with analysis of their safety, efficacy, treatment patterns and strengths and weaknesses. This includes a heat map comparing the drugs in terms of clinical trial results.
  • A comprehensive review of the pipeline for breast cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline for mAbs is analyzed on the basis of phase distribution, program type and molecular target, as is the entire pipeline for all molecule types.
  • Detailed analysis of pipeline drug clinical trials by trial size, trial duration and program failure rate for each molecule type and mechanism of action. Additionally, a detailed analysis of clinical trial endpoints is provided, detailing their importance in this disease area and their commercial relevance to currently marketed products.
  • Multi-scenario forecast data for the market is provided to 2019, which takes into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth
  • Complete analysis of licensing and co-development deals in this market, by year, value, molecule type, Phase and mechanism of action. Additionally, the international network of licensing deals in breast cancer is mapped out by geography.

Reasons to Buy

  • Understand the different indications for breast cancer, from early-stage to the metastatic disease
  • Grasp the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent, and the context of mAbs in the pipeline
  • Pinpoint the trends in clinical trial duration and size amongst clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for breast cancer therapeutics. Determine the risk associated with the development of mAbs compared to other molecule types.
  • Observe the shift in clinical trial endpoints by clinical Phase, and use this data to potentially influence any future developmental programs. Understand the importance of selecting the correct endpoints in the study of drugs for this disease.
  • Assess the potential clinical and commercial impact of recently-approved molecules on the breast cancer market and determine the potential revenues associated with the launch of a novel product, in addition to the level of competitiveness in the market.

Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Monoclonal Antibodies Market in Breast Cancer to 2019 – Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 10
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 11
2.6.1 Classification 13
2.7 Treatment Options 13
2.7.1 Surgery and Radiation Therapy 13
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 19

3 Marketed Products 20
3.1 Herceptin (Trastuzumab) – Hoffmann La Roche 20
3.2 Avastin (Bevacizumab) – Hoffmann La Roche 23
3.3 Kadcyla (Trastuzumab Emtansine) – Hoffmann La Roche 25
3.4 Perjeta (Pertuzumab) – Hoffmann La Roche 26
3.5 Xgeva (denosumab) – Amgen 27
3.6 Heat Map for Marketed Products 28
3.7 Conclusion 30

4 Pipeline for Breast Cancer Monoclonal Antibody Therapeutics 31
4.1 Overall Pipeline 32
4.2 Mechanisms of Action 34
4.3 Clinical Trials 37
4.3.1 Attrition Rate 37
4.3.2 Clinical Trial Size 38
4.3.3 Duration 40
4.3.4 Clinical Trial End-points 42
4.4 Promising Drug Candidates in the Pipeline 44
4.4.1 CDX-011 (glembatumumab vedotin) – Celldex Therapeutics 44
4.4.2 Metmab (onartuzumab) – Hoffman La Roche 44
4.4.3 Hu3S193 – Recepta Biopharma 44
4.4.4 MM-121 – Merrimack Pharmaceuticals 45
4.4.5 IMC-18F1 (Icrucumab) – Eli Lilly 45
4.4.6 Rexomun (Ertumaxomab) – Fresenius Biotech 45
4.4.7 Medi-573 (Dusigitumab) – Medimmune 45
4.4.8 MK-0646 (Dalotuzumab) – Merck and Co 46
4.4.9 LY3012217 (Cixutumumab) - Eli Lilly 46
4.5 Conclusion 46

5 Market Forecast to 2019 48
5.1 Global 48
5.1.1 Treatment Usage Patterns 48
5.1.2 Market Size 49
5.2 US 50
5.2.1 Treatment Usage Patterns 50
5.2.2 Market Size 51
5.3 Canada 52
5.3.1 Treatment Usage Patterns 52
5.3.2 Market Size 53
5.4 Europe 54
5.4.1 Treatment Usage Patterns 54
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 56
5.5 Japan 57
5.5.1 Treatment Usage Patterns 57
5.5.2 Market Size 58
5.6 Drivers and Barriers 59
5.6.1 Drivers 59
5.6.2 Barriers 59

6 Deals and Strategic Consolidations 60
6.1 R&D Licensing Agreements 60
6.1.1 Key Licensing Deals 63
6.2 Co-development Agreements 65
6.2.1 Key Deals 65

7 Appendix 68
7.1 References 68
7.2 References for Heat Map 73
7.3 All Pipeline Products, by Phase 74
7.3.1 Discovery 74
7.3.2 Preclinical 77
7.3.3 IND/CTA Filed and Phase I 89
7.3.4 Phase II 95
7.3.5 Phase III and Pre-Registration 102
7.4 Market Definitions 104
7.5 Abbreviations 105
7.6 Tabular Forecast Data 106
7.6.1 Global 106
7.6.2 US 106
7.6.3 Canada 106
7.6.4 UK 107
7.6.5 France 107
7.6.6 Germany 107
7.6.7 Italy 107
7.6.8 Spain 108
7.6.9 Japan 108
7.7 Research Methodology 109
7.7.1 Coverage 109
7.7.2 Secondary Research 109
7.8 Therapeutic Landscape 110
7.9 Epidemiology-Based Forecasting 110
7.10 Market Size by Geography 111
7.11 Geographical Landscape 112
7.12 Pipeline Analysis 112
7.13 Competitive Landscape 112
7.13.1 Expert Panel Validation 112
7.14 Contact Us 112
7.15 Disclaimer 112

List of Tables

Table 1: Market for mAbs in Breast Cancer, Global, TNM Staging, 2010–2013 11
Table 2: Market for mAbs in Breast Cancer, US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 12
Table 3: Market for mAbs in Breast Cancer, References for Heat Map (Figure 6) 73
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 74
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 77
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase I and IND/CTA filed), 2013 89
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 95
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-Registration), 2013 102
Table 9: Market for mAbs in Breast Cancer, Global, Forecast Data, 2012–2019 106
Table 10: Market for mAbs in Breast Cancer, US, Forecast Data, 2012–2019 106
Table 11: Market for mAbs in Breast Cancer, Canada, Forecast Data, 2012–2019 106
Table 12: Market for mAbs in Breast Cancer, UK, Forecast Data, 2012–2019 107
Table 13: Market for mAbs in Breast Cancer, France, Forecast Data, 2012–2019 107
Table 14: Market for mAbs in Breast Cancer, Germany, Forecast Data, 2012–2019 107
Table 15: Market for mAbs in Breast Cancer, Italy, Forecast Data, 2012–2019 107
Table 16: Market for mAbs in Breast Cancer, Spain, Forecast Data, 2012–2019 108
Table 17: Market for mAbs in Breast Cancer, Japan, Forecast Data, 2012–2019 108

List of Figures

Figure 1 Market for mAbs in Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III 17
Figure 2: Market for mAbs in Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV 18
Figure 3: Market for mAbs in Breast Cancer, Global, Sales of Herceptin ($bn), 1999–2012 21
Figure 4: Market for mAbs in Breast Cancer, Global, Sales of Avastin ($bn), 2004–2012 24
Figure 5: Market for mAbs in Breast Cancer, Global, Aggregate Sales of Xgeva and Prolia ($m), 2010–2012 27
Figure 6: Market for mAbs in Breast Cancer, Global, Heat Map (Marketed Products) 29
Figure 7: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 32
Figure 8: Market for mAbs in Breast Cancer, Global, mAbs by Mechanism of Action, 2013 34
Figure 9: Market for mAbs in Breast Cancer, Global, mAbs by Mechanism of Action (Growth Factor Inhibitors), 2013 35
Figure 10: Market for mAbs in Breast Cancer, Global, mAbs by Molecular Target (Targeted Cytotoxic), 2013 36
Figure 11: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 37
Figure 12: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 38
Figure 13: Market for mAbs in Breast Cancer, Global, Clinical Trial Size, 2013 39
Figure 14: Market for mAbs in Breast Cancer, Global, Clinical Trial Duration, 2006–2013 40
Figure 15: Market for mAbs in Breast Cancer, Global, Clinical Trial Durations, 2006–2013 41
Figure 16: Market for mAbs in Breast Cancer, Global, Clinical Trial Endpoints for Phases II and III, 2006–2012 42
Figure 17: Market for mAbs in Breast Cancer, Global, Clinical Trial Endpoints for Phases II and III per Product, 2006–2012 43
Figure 18: Market for mAbs in Breast Cancer, Global, Treatment Usage Patterns, 2012–2019 48
Figure 19: Market for mAbs in Breast Cancer, Global, Market Size ($bn), 2012–2019 49
Figure 20: Market for mAbs in Breast Cancer, US, Treatment Patterns, 2012–2019 50
Figure 21: Market for mAbs in Breast Cancer, US, Market Size ($bn), 2012–2019 51
Figure 22: Market for mAbs in Breast Cancer, Canada, Treatment Usage Patterns, 2012–2019 52
Figure 23: Market for mAbs in Breast Cancer, Canada, Market Size ($m), 2012–2019 53
Figure 24: Market for mAbs in Breast Cancer, Top Five European Markets, Treatment Usage Patterns, 2012–2019 54
Figure 25: Market for mAbs in Breast Cancer, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019 55
Figure 26: Market for mAbs in Breast Cancer, Top Five European Markets, Market Size ($m), 2012–2019 56
Figure 27: Market for mAbs in Breast Cancer, Japan, Treatment Usage Patterns, 2012–2019 57
Figure 28: Market for mAbs in Breast Cancer, Japan, Market Size ($m), 2012–2019 58
Figure 29: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (A) 60
Figure 30: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (B) 61
Figure 31: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (C) 62
Figure 32: Market for mAbs in Breast Cancer, Global, Co-development Deals (All Molecule Types) by Partner Country, 2006–2012 65
Figure 33: Market for mAbs in Breast Cancer, Global, Co-development Deals by Molecule Type, 2006–2012 66
Figure 34: GBI Research Market Forecasting Model 111

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2014
    Published: 31-Mar-2014        Price: US $2000 Onwards        Pages: 75
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2014', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug t......
  • Market Research Report on Global and Chinese Bicalutamide Industry, 2009-2019
    Published: 19-Mar-2014        Price: US $2400 Onwards        Pages: 150
    Market Research Report on Global and Chinese Bicalutamide Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Bicalutamide industry. The report firstly reviews the basic information of Bicalutamide including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Bicalutamide listing their product specification, capacity, Production value, and market share etc.; The report further analyzes q......
  • Market Research Report on Global and Chinese Anastrozole Industry, 2009-2019
    Published: 19-Mar-2014        Price: US $2400 Onwards        Pages: 150
    Market Research Report on Global and Chinese Anastrozole Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Anastrozole industry. The report firstly reviews the basic information of Anastrozole including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Anastrozole listing their product specification, capacity, Production value, and market share etc.; The report further analyzes quant......
  • Investigation Report on China Imatinib Market, 2009-2018
    Published: 4-Mar-2014        Price: US $1800 Onwards        Pages: 40
    Incidence of chronic myelogenous leukemia (CML) varies in the world. The global incidence is about 10/1,000,000 while in China it is 4/1,000,000. CML takes up about 20% of leukaemia in China and 95% of chronic leukemia. CML patients vary from the very young to the very old, and the incidence increases as people grow old. CML treatment went through a long period of development. Interferon used to be main medication before imatinib. It was initially used in CML treatment in 1980 and became the ......
  • Peritoneal Cancer – Pipeline Review, H1 2014
    Published: 28-Feb-2014        Price: US $2000 Onwards        Pages: 218
    Peritoneal Cancer - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Peritoneal Cancer - Pipeline Review, H1 2014', provides an overview of the Peritoneal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates......
  • Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2014
    Published: 28-Feb-2014        Price: US $2000 Onwards        Pages: 124
    Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug targe......
  • Neuroblastoma – Pipeline Review, H1 2014
    Published: 28-Feb-2014        Price: US $2000 Onwards        Pages: 235
    Neuroblastoma - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Neuroblastoma - Pipeline Review, H1 2014', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured n......
  • Metastatic Renal Cell Carcinoma – Pipeline Review, H1 2014
    Published: 28-Feb-2014        Price: US $2000 Onwards        Pages: 177
    Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014', provides an overview of the Metastatic Renal Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administr......
  • T-Cell Leukemia – Pipeline Review, H1 2014
    Published: 28-Feb-2014        Price: US $2000 Onwards        Pages: 79
    T-Cell Leukemia - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘T-Cell Leukemia - Pipeline Review, H1 2014', provides an overview of the T-Cell Leukemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and fe......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs